Business
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MCHP, TGTX, MGTI, HAS, CPB and ADNT
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MCHP, TGTX, MGTI, HAS, CPB and ADNT.
About this update from Mgt Capital Investments, Inc.
[{"type":"text","content":"\nNEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      \n Microchip Technology Inc. (NASDAQGS: MCHP) Class Period: March 2, 2018 to August 9, 2018 Lead Plaintiff Deadline: November 16, 2018 The lawsuit alleges that Microchip Technology Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Microsemi’s financial performance was underperforming Microchip’s expectations; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, including positive statements about Microsemi, were materially misleading and/or lacked a reasonable basis. Get additional information about the MCHP lawsuit: http://www.kleinstocklaw.com/pslra-1/microchip-technology-inc-loss-submission-form?wire=3 TG Therapeutics, Inc. (NASDAQCM: TGTX) Class Period: June 4, 2018 to September 25, 2018 Lead Plaintiff Deadline: December 3, 2018 According to the complaint, TG Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival. Get additional information about the TGTX lawsuit: http://www.kleinstocklaw.com/pslra-1/tg-therapeutics-inc-loss-submission-form?wire=3 MGT Capital Investments Inc. (OTCMKTS: MGTI) Class Period: October 9, 2015 to September 7, 2018 Lead Plaintiff Deadline: November 27, 2018 MGT Capital Investments Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in an illegal pump-and-dump scheme to artifici...